Connor Frey

20PUBLICATIONS
9CO-AUTHORS
AutoimmunityPharmacogenomicsHaematological tumoursMolecular targetsRespiratory diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Sep 16, 2026
Ocular Surface Disease as an Immune-related Adverse Event of Immune Checkpoint Inhibitor Therapy.

|Jul 10, 2026
Characterizing the post-market safety profile of lazertinib: a pharmacovigilance study of the FDA Adverse Events Reporting System Database.

|Jul 01, 2026
Immune effector cell-associated hematotoxicity following CAR-T cell therapies: insights from a large national database.

|May 23, 2026
Dermatomyositis predominates among checkpoint inhibitor-associated inflammatory myositis phenotypes: a pharmacovigilance disproportionality analysis identifies a class-wide signal.

|Apr 30, 2026
Association between immune-mediated cystitis and PD-1, PD-L1, CTLA-4, and LAG-3 immune checkpoint inhibitors: A pharmacovigilance study from the FAERS database.

|Apr 13, 2026
Comparative pharmacovigilance signals for PD-1, PD-L1, CTLA-4, and LAG-3 immune checkpoint inhibitor-associated hemophagocytic lymphohistiocytosis in the FAERS database.

Connor Frey

Pageof 4

Frequent Collaborators

4 joint publications

Mahyar Etminan

2 joint publications

Kenneth Ku

2 joint publications

Maor Arad

2 joint publications

Golfam Ghafourifar